Neuromuscular disorders of glycogen metabolism

Current Neurology and Neuroscience Reports

Volumn 13, Issue 3, 2013, Pages

  Gazzerro, Elisabetta ^a   Andreu, Antoni L ^b   Bruno, Claudio ^a  

^a Pediatric Neurology Unit   (Italy)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

AMP activated protein kinase; Autophagy; Branching enzyme; Cardiomyopathy; Danon disease; Debrancher; Exercise intolerance; Glycogen metabolism; Glycogen storage disease; Glycogen synthase; Glycogenin; Glycogenoses; Lafora bodies; Laforin; Malin; Myophosphorylase; Phosphofructokinase; Phosphoglycerate kinase; Phosphoglycerate mutase; Phosphorylase b kinase; Polyglucosan; Second wind phenomenon; Vacuolar myopathy; Weakness

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; GLYCOGEN;

ARTICLE; GLYCOGEN STORAGE DISEASE; GLYCOGEN STORAGE DISEASE TYPE 0; GLYCOGEN STORAGE DISEASE TYPE 3; GLYCOGEN STORAGE DISEASE TYPE 4; GLYCOGEN STORAGE DISEASE TYPE 5; GLYCOGEN STORAGE DISEASE TYPE 7; GLYCOGEN STORAGE DISEASE TYPE 8; GLYCOGEN STORAGE DISEASE TYPE 9; GLYCOGEN STORAGE DISEASE TYPE X; GLYCOGEN STORAGE DISEASE TYPE XI; GLYCOGEN STORAGE DISEASE TYPE XII; GLYCOGEN STORAGE DISEASE TYPE XIII; GLYCOGEN STORAGE DISEASE TYPE XIV; GLYCOGEN STORAGE DISEASE TYPE XV; GLYCOGEN SYNTHESIS; GLYCOGENOLYSIS; GLYCOLYSIS; MYOCLONUS EPILEPSY; NONHUMAN; SKELETAL MUSCLE; ANIMAL; DISEASE MODEL; HUMAN; LYSOSOME STORAGE DISEASE; METABOLISM; MUSCLE DISEASE; NEUROMUSCULAR DISEASE; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; DISEASE MODELS, ANIMAL; GLYCOGEN; GLYCOGEN STORAGE DISEASE; HUMANS; LYSOSOMAL STORAGE DISEASES; MUSCULAR DISEASES; NEUROMUSCULAR DISEASES;

MLCS; MLOWN;

EID: 84872261395     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-012-0333-0     Document Type: Article

References (75)

1. Roach PJ. Glycogen and i (Pubitemid 34649835)
2. DiMauro S, Spiegel R. Progress and problems in muscle glycoge-noses. Acta Myol. 2011; 30: 96-102.
3. DiMauro S, Garone C. Metabolic disorders of fetal life: glycogenoses and mitochondrial defects of the mitochondrial respiratory chain. Semin Fetal Neonatal Med. 2011; 16: 181-9.
4. Roach PJ, Depaoli-Roach AA, Hurley T.D., Tagliabracci VS. Glycogen and its metabolism: some new developments and old themes. Biochem J. 2012; 441: 763-87.
5. van der Ploeg AT, Reuser AJ. Pompe's disease. Lancet. 2008; 372: 1342-53.
6. Moslemi AR, Lindberg C, Nilsson J., et al. Glycogenin-1 deficiency and inactivated priming of glycogen synthesis. N Engl J Med. 2010; 362: 1203-10.
7. Nilsson J, Halim A, Moslemi A.R., et al. Molecular pathogenesis of a new glycogenosis caused by a glycogenin-1 mutation. Biochim Biophys Acta. 2012; 1822: 493-9.
8. Kollberg G, Tulinius M, Gilljam T., et al. Cardiomyopathy and exercise intolerance in muscle glycogen storage disease 0. N Engl J Med. 2007; 357: 1507-14. (Pubitemid 47572636)
9. Pederson BA, Chen H, Schroeder J.M., et al. Abnormal cardiac development in the absence of heart glycogen. Mol Cell Biol. 2004; 24: 7179-87. (Pubitemid 39014443)
10. Moses SW, Parvari R. The variable presentations of glycogen storage disease type IV: A review of clinical, enzymatic and molecular studies. Curr Mol Med. 2002; 2: 177-88. (Pubitemid 34649839)
11. Bruno C, Cassandrini D, Assereto S., et al. Neuromuscular forms of glycogen branching enzyme deficiency. Acta Myol. 2007; 26: 75-8. (Pubitemid 47400732)
12. Magoulas PL, El-Hattab AW, Roy A., et al. Diffuse reticuloendo-thelial system involvement in type IV glycogen storage disease with a novel GBE1 mutation: A case report and review. Hum Pathol. 2012; 43: 943-51.
13. Bruno C, van Diggelen OP, Cassandrini D, et al. Clinical and genetic heterogeneity of branching enzyme deficiency (glycoge-nosis type IV). Neurology. 2004; 63: 1053-8. (Pubitemid 39287914)
14. Reusche E, Aksu F, Goebel H.H., et al. A mild juvenile variant of type IV glycogenosis. Brain Dev. 1992; 14: 36-43.
15. Servidei S, Riepe RE, Langston C, et al. Severe cardiopathy in branching enzyme deficiency. J Pediatr. 1987; 111: 51-516.
16. Goebel HH, Shin YS, Gullotta F, et al. Adult polyglucosan body myopathy. J Neuropathol Exp Neurol. 1992; 51: 24-35.
17. Lossos A, Barash V, Soffer D., et al. Hereditary branching enzyme dysfunction in adult polyglucosan body disease: A possible metabolic cause in two patients. Ann Neurol. 1991; 30: 655-62.
18. Bruno C, Servidei S, Shanske S., et al. Glycogen branching enzyme deficiency in adult polyglucosan body disease. Ann Neurol. 1993; 33: 88-93. (Pubitemid 23009914)
19. Taratuto AL, Akman HO, Saccoliti M, Riudavets M., Arakaki N, Mesa L, Sevlever G., Goebel H, DiMauro S. Branching enzyme deficiency/glycogenosis storage disease type IV presenting as a severe congenital hypotonia: muscle biopsy and autopsy findings, biochemical and molecular genetic studies. Neuromuscul Disord. 2010; 20: 783-90.
20. Fyfe JC, Giger U, Van Winkle TJ, et al. Glycogen storage disease type IV: inherited deficiency of branching enzyme activity in cats. Pediatr Res. 1992; 32: 719-25.
21. Ward TL, Valberg SJ, Adelson D.L., et al. Glycogen branching enzyme (GBE1) mutation causing equine glycogen storage disease IV. Mamm Genome. 2004; 15: 570-7. (Pubitemid 38798848)
22. Lee YC, Chang CJ, Bali D, et al. Glycogen-branching enzyme deficiency leads to abnormal cardiac development: novel insights into glycogen storage disease IV. Hum Mol Genet. 2011; 20: 455-65.
23. Akman HO, Sheiko T, Tay S.K., et al. Generation of a novel mouse model that recapitulates early and adult onset glycogenosis type IV. Hum Mol Genet. 2011; 20: 4430-9.
24. Goldstein J, Austin S, Kishnani P., Bali D. Phosphorylase kinase deficiency. In: Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP, editors. GeneReviews" [Internet]. Seattle: University of Washington; 1993-2011 May 31. This is a comprehensive review of physiopathological and clinical features of glycogenosis type VIII.
25. Wehner M, Clemens PR, Engel A.G., Kilimann MW. Human muscle glycogenosis due to phosphorylase kinase deficiency associated with a nonsense mutation in the muscle isoform of the alpha subunit. Hum Mol Genet. 1994; 3: 1983-7. (Pubitemid 24341375)
26. Bruno C, Manfredi G, Andreu A.L., et al. A splice junction mutation in the alpha(M) gene of phosphorylase kinase in a patient with myopathy. Biochem Biophys Res Commun. 1998; 249: 648-51. (Pubitemid 28441892)
27. Burwinkel B, Hu B, Schroers A., et al. Muscle glycogenosis with low phosphorylase kinase activity: mutations in PHKA1, PHKG1 or six other candidate genes explain only a minority of cases. Eur J Hum Genet. 2003; 11: 516-26. (Pubitemid 36896580)
28. Wuyts W, Reyniers E, Ceuterick C., Storm K, de Barsy T, Martin JJ. Myopathy and phosphorylase kinase deficiency caused by a mutation in the PHKA1 gene. Am J Med Genet A. 2005; 133: 82-4. (Pubitemid 40175571)
29. Echaniz-Laguna A., Akman HO, et al. Muscle phosphorylase b kinase deficiency revisited. Neuromuscul Disord. 2010; 20: 125-7.
30. Ørngreen MC, Schelhaas HJ, Jeppesen TD, et al. Is muscle glyco-genolysis impaired in X-linked phosphorylase b kinase deficiency? Neurology. 2008; 70: 1876-82. (Pubitemid 351684658)
31. Preisler N, Orngreen MC, Echaniz-Laguna A, et al. Muscle phos-phorylase kinase deficiency: A neutral metabolic variant or a disease? Neurology. 2012; 78: 265-8.
32. Arenas J, Martín MA, Andreu AL. Glycogen storage disease type V. In: Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP, editors. GeneReviews™ [Internet]. Seattle: University of Washington; 1993-2006 Apr 19 (updated 12 May 2009).
33. Lucia A, Ruiz JR, Santalla A, et al. Genotypic and phenotypic features of McArdle disease: insights from the Spanish national registry. J Neurol Neurosurg Psychiatry. 2012; 83: 322-8.
34. Nogales-Gadea G., Rubio JC, Fernandez-Cadenas I, et al. Expression of the muscle glycogen phosphorylase gene in patients with McArdle disease: the role of nonsense-mediated mRNA decay. Hum Mutat. 2008; 29: 277-83. (Pubitemid 351240600)
35. Bruno C, Cassandrini D, Martinuzzi A., et al. McArdle disease: the mutation spectrum of PYGM in a large Italian cohort. Hum Mutat. 2006; 27: 718.
36. Vissing J, Duno M, Schwartz M., Haller RG Splice mutations preserve myophosphorylase activity that ameliorates the pheno-type in McArdle disease. Brain. 2009; 132: 1545-52.
37. Quinlivan R, Buckley J, James M., et al. McArdle disease: A clinical review. J Neurol Neurosurg Psychiatry. 2010; 81: 1182-8.
38. Haller RG, Vissing J. Spontaneous "second wind" and glucose-induced second "second wind" in McArdle disease: oxidative mechanisms. Arch Neurol. 2002; 59: 1395-402. (Pubitemid 35014803)
39. Lucia A, Nogales-Gadea G, Perez M., et al. McArdle disease: what do neurologists need to know? Nat Clin Pract Neurol. 2008; 4: 568-77. This is a comprehensive review of clinical features and management aspects of glycogenosis type V.
40. Angelos S, Valberg SJ, Smith B.P., et al. Myophosphorylase deficiency associated with rhabdomyolysis and exercise intolerance in 6 related charolais cattle. Muscle Nerve. 1995; 18: 736-40.
41. Tan P, Allen JG, Wilton S.D., et al. A splice-site mutation causing ovine McArdle's disease. Neuromuscul Disord. 1997; 7: 336-42. (Pubitemid 27375839)
42. Nogales-Gadea G., Pinós T, Lucia A., et al. Knock-in mice for the R50X mutation in the PYGM gene present with McArdle disease. Brain. 2012; 135: 2048-57.
43. Kishnani PS, Austin SL, Arn P, et al. Glycogen storage disease type III diagnosis and management guidelines. Genet Med. 2010; 12: 446-63. This is a comprehensive review of physiopatho-logical and clinical features of glycogenosis type III
44. Goldstein JL, Austin SL, Boyette K, et al. Molecular analysis of the AGL gene: identification of 25 novel mutations and evidence of genetic heterogeneity in patients with glycogen storage disease type III. Genet Med. 2010; 12: 424-30.
45. Vertilus SM, Austin SL, Foster K.S., et al. Echocardiographic manifestations of glycogen storage disease III: increase in wall thickness and left ventricular mass overtime. Genet Med. 2010; 12: 413-23.
46. Gregory BL, Shelton GD, Bali D.S., Chen YT, Fyfe JC. Glycogen storage disease type IIIa in curly-coated retrievers. J Vet Intern Med. 2007; 21: 40-6.
47. Yi H, Thurberg BL, Curtis S, et al. Characterization of a canine model of glycogen storage disease type IIIa. Dis Model Mech. 2012; 5: 804-11.
48. Nakajima H, Raben N, Hamaguchi T., Yamasaki T. Phosphofructokinase deficiency; past, present and future. Curr Mol Med. 2002; 2: 197-212. (Pubitemid 34649841)
49. Toscano A, Musumeci O. Tarui disease and distal glycogenoses: clinical and genetic update. Acta Myol. 2007; 26: 105-7. (Pubitemid 351271104)
50. Haller RG, Vissing J. No spontaneous second wind in muscle phosphofructokinase deficiency. Neurology. 2004; 62(1): 82-6. (Pubitemid 38082875)
51. Musumeci O, Bruno C, Mongini T., et al. Clinical features and new molecular findings in muscle phosphofructokinase deficiency (GSD type VII). Neuromuscul Disord. 2012; 22: 325-30.
52. García M., Pujol A, Ruzo A., et al. Phosphofructo-1-kinase deficiency leads to a severe cardiac and hematological disorder in addition to skeletal muscle glycogenosis. PLoS Genet. 2009; 5: e1000615.
53. Beutler E. PGK deficiency. Br J Haematol. 2007; 136: 3-11. (Pubitemid 44912583)
54. Spiegel R, Area Gomez E, Akman HO, et al. Myopathic form of phosphoglycerate kinase (PGK) deficiency: A new case and pathogenic considerations. Neuromusc Disord. 2009; 19: 207-11.
55. Sotiriou E, Greene P, Krishna S., et al. Myopathy and parkinsonism in phosphoglycerate kinase deficiency. Muscle Nerve. 2010; 41: 707-10.
56. Naini A, Toscano A, Musumeci O., et al. Muscle phosphoglycerate mutase deficiency revisited. Arch Neurol. 2009; 66: 394-8.
57. Kanno T, Maekawa M. Lactate dehydrogenase M-subunit deficiencies: clinical features, metabolic background, and genetic heterogeneities. Muscle Nerve. 1995; 3: S54-60.
58. Kreuder J, Borkhardt A, Repp R., et al. Inherited metabolic myop-athy and hemolysis due to a mutation in aldolase a. N Engl J Med. 1996; 334: 1100-4. (Pubitemid 26120188)
59. Comi GP, Fortunato F, Lucchiari S., et al. Beta-enolase deficiency, a new metabolic myopathy of distal glycolysis. Ann Neurol. 2001; 50: 202-7. (Pubitemid 32738145)
60. Stojkovic T, Vissing J, Petit F., et al. Muscle glycogenosis due to phosphoglucomutase 1 deficiency. N Engl J Med. 2009; 361: 425-7. The is the first description of this new glycogen disorder.
61. Delgado-Escueta AV. Advances in Lafora progressive myoclonus epilepsy. Curr Neurol Neurosci Rep. 2007; 7: 428-33. (Pubitemid 47422785)
62. Minassian BA, Lee JR, Herbrick J.A., et al. Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy. Nat Genet. 1998; 20: 171-4. (Pubitemid 28455450)
63. Vilchez D, Ros S, Cifuentes D., et al. Mechanism suppressing glycogen synthesis in neurons and its demise in progressive my-oclonus epilepsy. Nat Neurosci. 2007; 10: 1407-13. (Pubitemid 350014686)
64. DePaoli-Roach A.A., Tagliabracci VS, Segvich D.M., et al. Genetic depletion of the malin E3 ubiquitin ligase in mice leads to Lafora bodies and the accumulation of insoluble laforin. J Biol Chem. 2010; 285: 25372-81.
65. Turnbull J, Wang P, Girard J.M., et al. Glycogen hyperphosphorylation underlies Lafora body formation. Ann Neurol. 2010; 68: 925-33. This article defines the relevance of glycogen phosphate accumulation in a mouse model of malin deficiency.
66. Ganesh S, Delgado-Escueta AV, Sakamoto T., et al. Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice. Hum Mol Genet. 2002; 11: 1251-62. (Pubitemid 34555522)
67. Tagliabracci VS, Turnbull J, Wang W., et al. Laforin is a glycogen phosphatase, deficiency of which leads to elevated phosphorylation of glycogen in vivo. Proc Natl Acad Sci USA. 2007; 104: 19262-6. This article defines the relevance of glycogen phosphate accumulation in a mouse model of laforin deficiency.
68. Puri R, Ganesh S. Autophagy defects in Lafora disease: cause or consequence? Autophagy. 2012; 8: 289-90.
69. Delgado-Escueta AV. Lafora progressive myoclonus epilepsy: gly-cogen storage disease vs neurodegenerative disease. Neurology. 2012; 79: 21-2.
70. Hardie DG. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev. 2011; 25: 1895-908.
71. Scott JW, Norman DG, Hawley S.A., Kontogiannis L., Hardie DG. Protein kinase substrate recognition studied using the recombinant catalytic domain of AMP-activated protein kinase and a model substrate. J Mol Biol. 2002; 317: 309-23. (Pubitemid 34722196)
72. Arad M, Benson DW, Perez-Atayde AR, McKenna W.J., et al. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest. 2002; 109: 357-62. (Pubitemid 34141809)
73. Akman HO, Sampayo JN, Ross F.A., et al. Fatal infantile cardiac glycogenosis with phosphorylase kinase deficiency and a mutation in the gamma2-subunit of AMP-activated protein kinase. Pediatr Res. 2007; 62: 499-504. (Pubitemid 47476213)
74. Arad M, Moskowitz IP, Patel V.V., et al. Transgenic mice over-expressing mutant PRKAG2 define the cause of Wolff-Parkinson-white syndrome in glycogen storage cardiomyopathy. Circulation. 2003; 107: 2850-6. (Pubitemid 36705997)
75. Costford SR, Kavaslar N, Ahituv N, et al. Gain-of-function R225W mutation in human AMPKgamma(3) causing increased glycogen and decreased triglyceride in skeletal muscle. PLoS One. 2007; 2: e903.